Deschatelets Pascal 4
4 · Apellis Pharmaceuticals, Inc. · Filed May 21, 2024
Insider Transaction Report
Form 4
Deschatelets Pascal
Chief Scientific Officer
Transactions
- Exercise/Conversion
Common Stock
2024-05-20$3.76/sh+24,500$92,120→ 1,140,483 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-05-20−24,500→ 12,780 totalExercise: $3.76Exp: 2026-02-06→ Common Stock (24,500 underlying)
Footnotes (1)
- [F1]This stock option was granted on 02/08/2016 and is fully vested.